Predictors of cardiovascular events in multiple myeloma: a systematic review and exploratory meta-analysis
- 1Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
- 2School of Nursing, Tongji Medical College of Huazhong University of Science and Technology
- 3Yangtze University Health Science Center
Abstract
Background: Novel therapies have significantly improved survival in patients with multiple myeloma (MM), but cardiovascular (CV) events have become a major challenge, impairing treatment continuity and increasing mortality. This systematic review aimed to identify predictors of CV events in MM to support risk stratification and cardio-oncology management.
Methods: This review followed PRISMA guidelines and was registered in PROSPERO (CRD420251084727). Five electronic databases were searched from inception to August 2025. Studies reporting multivariable predictors of CV events in MM were included. Methodological quality was assessed using QUIPS tool.
Results: Eleven studies were included, comprising nine retrospective cohort studies, one prospective observational study, one case-control study. Overall, most studies were judged to be at moderate risk of bias. A total of 20 candidate predictors of CV events were identified. Among these, six were reported in at least two studies, but only hypertension had sufficiently comparable adjusted effect estimates for exploratory meta-analysis. Among treatment-related factors, carfilzomib-based therapy and longer duration of proteasome-inhibitor treatment were associated with a higher risk of CV event in individual studies. Limited evidence from a single prospective study suggests that dynamic natriuretic peptide assessment may have prognostic value, with elevation of natriuretic peptides during the first treatment cycle showing a stronger predictive value (HR 9.5) compared to baseline elevation alone (HR 4.1).
Conclusions: CV risk in MM appears to be multifactorial, involving both pre-existing vulnerability and treatment-related toxicity. Although several candidate predictors have been identified, the current evidence remains limited by heterogeneity and methodological weaknesses. Larger prospective multicenter studies are required to validate these predictors and to define standardized CV risk assessment and surveillance strategies in MM.
Systematic Review Registration: identifier CRD420251084727.
Related
- Exploratory Identification of Potential Serum Biomarkers Associated with Relapse in Multiple Myeloma.
- Modifiable Cardiovascular Risk Factors and Hemorrhagic Presentation in Dural Arteriovenous Fistulas: A Systematic Review With Exploratory Quantitative Synthesis
- Head-to-Head Comparison Between [18F]FDG and [68Ga]Ga-Pentixafor PET/CT in Multiple Myeloma: A Systematic Review and Meta-Analysis
- Impact of Genetic Polymorphisms on Bortezomib-Induced Peripheral Neuropathy in Multiple Myeloma: A Systematic Review and Bioinformatics Analysis
- Progressive multifocal leukoencephalopathy, bispecific antibodies, and multiple myeloma: a case report and systematic review of the literature
BibTeX
@article{lv2026predictors,
title = {{Predictors of cardiovascular events in multiple myeloma: a systematic review and exploratory meta-analysis}},
author = {Tiantian Lv and Minjie Liu and Weiwei Zhang and Jie Zhang and Yun Fang},
journal = {Frontiers in Cardiovascular Medicine},
year = {2026},
month = oct,
doi = {10.3389/fcvm.2026.1925889},
url = {https://www.frontiersin.org/articles/10.3389/fcvm.2026.1925889/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Predictors of cardiovascular events in multiple myeloma: a systematic review and exploratory meta-analysis
AU - Tiantian Lv
AU - Minjie Liu
AU - Weiwei Zhang
AU - Jie Zhang
AU - Yun Fang
PY - 2026
DA - 2026/10/20
JO - Frontiers in Cardiovascular Medicine
DO - 10.3389/fcvm.2026.1925889
UR - https://www.frontiersin.org/articles/10.3389/fcvm.2026.1925889/full
AB - Background: Novel therapies have significantly improved survival in patients with multiple myeloma (MM), but cardiovascular (CV) events have become a major challenge, impairing treatment continuity and increasing mortality. This systematic review aimed to identify predictors of CV events in MM to support risk stratification and cardio-oncology management. Methods: This review followed PRISMA guidelines and was registered in PROSPERO (CRD420251084727). Five electronic databases were searched from inception to August 2025. Studies reporting multivariable predictors of CV events in MM were included. Methodological quality was assessed using QUIPS tool. Results: Eleven studies were included, comprising nine retrospective cohort studies, one prospective observational study, one case-control study. Overall, most studies were judged to be at moderate risk of bias. A total of 20 candidate predictors of CV events were identified. Among these, six were reported in at least two studies, but only hypertension had sufficiently comparable adjusted effect estimates for exploratory meta-analysis. Among treatment-related factors, carfilzomib-based therapy and longer duration of proteasome-inhibitor treatment were associated with a higher risk of CV event in individual studies. Limited evidence from a single prospective study suggests that dynamic natriuretic peptide assessment may have prognostic value, with elevation of natriuretic peptides during the first treatment cycle showing a stronger predictive value (HR 9.5) compared to baseline elevation alone (HR 4.1). Conclusions: CV risk in MM appears to be multifactorial, involving both pre-existing vulnerability and treatment-related toxicity. Although several candidate predictors have been identified, the current evidence remains limited by heterogeneity and methodological weaknesses. Larger prospective multicenter studies are required to validate these predictors and to define standardized CV risk assessment and surveillance strategies in MM. Systematic Review Registration: identifier CRD420251084727.
SN - 2297-055X
ER -